Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own”
Key takeaways
- A caller asked about Cramer’s thoughts on the stock, and he replied:
- Now, I gotta tell you something, I was shocked at the decline in this.
- Boston Scientific Corporation (NYSE:BSX) manufactures medical devices for different fields, including cardiology, neurology, and urology.
Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own” Syeda Seirut Javed Tue, June 23, 2026 at 9:41 PM GMT+7 1 min read BSX ABT MDT Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. A caller asked about Cramer’s thoughts on the stock, and he replied:
Now, I gotta tell you something, I was shocked at the decline in this. They have this one really good product. The sales didn’t come through, and the stock has been on a major… decline, but so has Abbott, so has Medtronic. The device sector is from Hades. If you’re willing to wait, I still don’t know when their next edition’s going to come out to make you feel better… This whole cohort is just too hard to own. And when I see that, what I think is somebody knows something I don’t. I hate that. I say no to Boston Scientific.
Boston Scientific Corporation (NYSE:BSX) manufactures medical devices for different fields, including cardiology, neurology, and urology. Some of the company’s products include heart-monitoring implants, spinal cord stimulators, and diagnostic tools for gastrointestinal conditions and cancer treatment.